List view / Grid view
Small biopharma companies often need to partner with larger firms to achieve their goals, but such agreements can fail if preparations are poor. Here, Diane Seimetz and Jörg Schneider at Biopharma Excellence discuss how due diligence smooths the path to collaboration.
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-300x278.jpg)
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-e1652444508201.jpg)
Roche shares initiative commitments that will extend prophylactic treatment access to patients with haemophilia, as well as investments to provide testing capabilities for HIV and Tuberculosis in developing countries.
As the face of healthcare changes and the emphasis on more-targeted remedies and preventative care increases, pharma’s traditional role in healthcare must also evolve. Here, Vintura Consultancy’s Gérard Klop looks at how pharma might carve out a new role in a more value-based healthcare market.
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
According to a new report, the orphan drug market is growing more than twice as fast as the non-orphan market and, by 2026, orphan drug sales will account for 20 percent of all prescription drug sales.
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
Dr Owen Seddon, Consultant in Infectious Diseases and Medical Microbiology at University Hospital of Wales, explains how successes in the development of the coronavirus vaccine must be used in the fight against other vaccine preventable disease.
A new age of sustainability: discover how ACC’s PyroSmart NextGen® recombinant Cascade Reagent (rCR) enhances bacterial endotoxin testing (BET).
Features in this issue discuss how bioprocessing must adapt to meet the needs of autologous cell therapies, the role of mass spectrometry in enhancing antibody consistency and the economic benefits of embracing continuous manufacturing. Also in this journal, articles exploring the development of precision medicine for chronic diseases, why acoustic…
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Best estimates suggest counterfeit drugs may account for as much as 50 percent of the sold online and 10 percent of those in circulation worldwide. With counterfeiters primarily replicating packaging to sell imitation products, here Ketaki Badhire of Future Market Insights explores the development of intelligent packaging in combatting counterfeit…
To ensure the UK’s prominence in the cell and gene therapy arena, the CGT Catapult has published a roadmap for the research and adoption of these cutting-edge therapies.
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics-300x278.jpg)
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics.jpg)
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
Growing pharma and biotech R&D investments, and a drive to improve efficiency are driving growth in the global laboratory robotics market.
How long until pharmaceuticals are widely 3D printed commercially? What are the key formulation considerations when applying 3D printing? Tune in to learn about all this and more...
